Covid 19 Research using Clinical Trials (Home Page)
Report for D001327: Autoimmune Diseases NIH
(Synonyms: Autoim, Autoimmune, Autoimmune Diseases)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (6)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1981 | Questionnaire by phone call Wiki | 0.58 |
| drug473 | COVID-19 diagnostic test Wiki | 0.58 |
| drug471 | COVID-19 convalescent hyperimmune plasma Wiki | 0.58 |
| drug1634 | Non-convalescent fresh frozen plasma (Standard plasma) Wiki | 0.58 |
| drug560 | Chloroquine Wiki | 0.20 |
| drug1853 | Placebo oral tablet Wiki | 0.11 |
Correlated MeSH Terms (12)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012859 | Sjogren's Syndrome NIH | 0.82 |
| D025241 | Spondylarthritis NIH | 0.58 |
| D008180 | Lupus Erythematosus, Systemic NIH | 0.47 |
| D001167 | Arteritis NIH | 0.41 |
| D012213 | Rheumatic Fever NIH | 0.41 |
| D001168 | Arthritis NIH | 0.33 |
| D011111 | Polymyalgia Rheumatica NIH | 0.33 |
| D013700 | Giant Cell Arteritis NIH | 0.33 |
| D003095 | Collagen Diseases NIH | 0.29 |
| D015535 | Arthritis, Psoriatic NIH | 0.29 |
| D012216 | Rheumatic Diseases NIH | 0.26 |
| D001172 | Arthritis, Rheumatoid NIH | 0.22 |
Correlated HPO Terms (5)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002960 | Autoimmunity HPO | 1.00 |
| HP:0002725 | Systemic lupus erythematosus HPO | 0.47 |
| HP:0012089 | Arteritis HPO | 0.41 |
| HP:0001369 | Arthritis HPO | 0.33 |
| HP:0001370 | Rheumatoid arthritis HPO | 0.22 |
There are 3 clinical trials
Clinical Trials
1 Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease
This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients with a history of systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome or psoriatic arthritis, during the epidemic period in France. The information is gathered using a standardized questionnaire, by phone call.
NCT04345159 SARS-CoV-2 Systemic Lupus Erythematosus Rheumatoid Arthritis Sjogren's Syndrome Psoriatic Arthritis Other: Questionnaire by phone call MeSH:Arthritis Arthritis, Psoriatic Sjogren's Syndrome Lupus Erythematosus, Systemic Autoimmune Diseases
HPO:Arthritis Autoimmunity Polyarticular arthritis Systemic lupus erythematosus
Primary Outcomes
Description: Adjusted Odds Ratio measuring the association between an exposure to long-term hydroxychloroquine intake and a history of symptoms compatible with a COVID-19 infection.
Measure: Adjusted Odds Ratio Time: 4 months after inclusion
2 Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases : a Retrospective Multicenter Observational Study
Primary Outcomes
Description: Adjusted Odds Ratio measuring the association between an exposure to long-term hydroxychloroquine intake and a history of symptoms compatible with a COVID-19 infection.
Measure: Adjusted Odds Ratio Time: 4 months after inclusionSince December 2019, an international outbreak of respiratory illnesses caused by SARS-CoV-2 called covid-19 has become a global challenge. In France, while the first cases were reported in January, more than 20 000 cases were confirmed at end of March. Early estimations from epidemiological data seem to show that 18-20% of patients with confirmed covid-19 are admitted in an intensive care unit (ICU). Patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases are susceptible to severe covid-19 (i.e ICU) due to the specific therapeutic management of their illness (corticosteroid, immunosuppressive and immunomodulatory drugs,..). No data are available for this particular population in France. This retrospective multicentre observational study aims to evaluate the frequency of severe forms of covid-19 and risk factors associated with specific outcomes in covid-19 in patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases.
NCT04353609 Sars-CoV2 Chronic Inflammatory Rheumatism Autoimmune Diseases MeSH:Rheumatic Fever Rheumatic Diseases Collagen Diseases Autoimmune Diseases
HPO:Autoimmunity
Primary Outcomes
Measure: Proportion of patients presenting a severe form of covid-19 requiring an intensive care unit admission or leading to death Time: From Baseline up to Day 21 after first symptoms of covid-19
Secondary Outcomes
Measure: Proportion of patients who die from a severe form of covid-19 Time: From Baseline up to Day 21 after first symptoms of covid-19
Measure: Proportion of patients who present an history of diabetes according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present obesity (validated by Body Mass Index value > 30 kg/cm2) Time: At the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Chronic Pulmonary Obstructive Disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Asthma according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Hypertension according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of cardiac disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Pulmonary Interstitial Disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of stroke according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of angiotensin-converting-enzyme inhibitor according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of cancer according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
3 Prevalence, Seroconversion and Impact of COVID-19 in Autoimmune Diseases in Europe
Primary Outcomes
Measure: Proportion of patients presenting a severe form of covid-19 requiring an intensive care unit admission or leading to death Time: From Baseline up to Day 21 after first symptoms of covid-19Secondary Outcomes
Measure: Proportion of patients who die from a severe form of covid-19 Time: From Baseline up to Day 21 after first symptoms of covid-19Measure: Proportion of patients who present an history of diabetes according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present obesity (validated by Body Mass Index value > 30 kg/cm2) Time: At the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Chronic Pulmonary Obstructive Disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Asthma according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Hypertension according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of cardiac disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Pulmonary Interstitial Disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of stroke according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of angiotensin-converting-enzyme inhibitor according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of cancer according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
The coronavirus disease 2019 (COVID-19) pandemic is a potentially fatal disease that represents a great global public health concern. In European countries such as Spain, Italy, Germany, Portugal, England and France, the pandemic has been of utmost importance. To date, no treatment has been robustly validated, and two theoretically opposite therapeutic strategies are proposed, based either on antiretroviral therapy or on immunomodulating agents. In this complex context, people living with immune-mediated inflammatory diseases (IMID) raise specific concerns due to their potentially increased risk of infections or of severe infections. Among IMID, Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, spondyloarthritis and giant cell arteritis are some key diseases. In this cross-sectional, observational, multi-centric study, the investigators aim to assess both clinical and serological prevalence of COVID-19 among samples of IMID patients in Europe. In parallel, the investigators aim to compare the prevalence of COVID-19 seroconversion across these five IMIDs, their penetration across different 6 European countries (France, Italy, Spain, Germany, United Kingdom and Portugal), and to assess the severity of COVID-19 in these patients. Moreover, changes in treatment will be assessed, including immunomodulatory tapering or discontinuation, its causes over the outbreak period, as well as the incidence of IMID flares and their severity over this same period. Finally, patient's perceptions towards the pandemic will be evaluated and compared to medication beliefs. Data will be collected through questionnaires during medical visit or phone consultation and serological tests will be performed within routine blood collection. As so, all study procedures are comprised within usual care. Through this study the investigators expect to have a better knowledge of the clinical and serological prevalence of COVID-19 in IMID across Europe, along with the psychological, clinical, and therapeutic impact of COVID-19 in this particular patient population.
NCT04397237 COVID-19 Systemic Lupus Erythematosus Sjogren's Syndrome Axial Spondyloarthritis Rheumatoid Arthritis Giant Cell Arteritis MeSH:Arthritis Arthritis, Rheumatoid Sjogren's Syndrome Spondylarthritis Polymyalgia Rheumatica Giant Cell Arteritis Arteritis Lupus Erythematosus, Systemic Autoimmune Diseases
HPO:Arteritis Arthritis Autoimmunity Polyarticular arthritis Rheumatoid arthritis Systemic lupus erythematosus
Primary Outcomes
Description: ELISA tests for COVID-19 antibodies
Measure: COVID-19 seroconversion Time: 1 day, during routine blood collection
Description: Case report form filled by the health professional
Measure: COVID-19 infection Time: During medical visit or phone consultation, up to 2 hours
Secondary Outcomes
Description: Descriptive analysis for each disease's rate
Measure: Seroconversion rate by disease Time: 1 day, during routine blood collection
Description: Descriptive analysis for each country's rate
Measure: Penetration across Europe Time: 1 day, during routine blood collection
Description: World Health Organization ordinal scale for clinical improvement at any given point of the infection, going from 0 to 8, where higher scores means worse outcome.
Measure: COVID-19 severity Time: During medical visit, up to 1 hour
Description: Descriptive analysis for overall and COVID-19-linked mortality rates
Measure: COVID-19 mortality rate Time: During contact with family members, up to 1 hour
Description: Case report form filled by the health professional
Measure: COVID-19 impact on immunomodulatory treatment Time: During medical visit, up to 1 hour
Description: Case report form filled by the patient
Measure: Patient-reported flares Time: During medical visit, up to 1 hour
Description: Fear of COVID-19 scale, going from 7 to 35, where higher scores means worse outcome.
Measure: Patient's fears towards COVID-19 Time: During medical visit, up to 1 hour
Description: Beliefs about Medicines Questionnaire, going from 11 to 55, with higher scores indicating stronger beliefs regarding medicine.
Measure: Patient's beliefs in their medicines towards COVID-19 Time: During medical visit, up to 1 hour
HPO Nodes
HP:0002960: Autoimmunity
Genes 218
KMT2D IL2RA ARHGEF1 NHEJ1 STAT3 IL2RB CD19 C1QA CASP10 CTLA4 C4A TTC7A GPR35 CD81 PNP RAG2 ADA2 SERPING1 PTPN22 CD247 SERPING1 LRBA CCR6 TTC7A CD19 IL6 RREB1 PTPN22 SAMHD1 TNFRSF13B TCF4 SEC23B FADD DCLRE1C PLCG2 CTLA4 HLA-DRB1 ICOS NRAS TNFRSF13C HLA-DRB1 MMP2 RFXAP LIG4 TRAC IL7R IL2RA LACC1 IRF5 CSF2RB FLT1 FASLG CD3G HAVCR2 TREX1 SMPD1 KIAA0319L CORIN FAS IL6 ARVCF ACP5 ZAP70 RAG2 C1R NFKB2 MST1 MTHFD1 ADA ANKRD55 RAG1 TPP2 ITCH CSF2RA PTPN22 TNFAIP3 FAS TBX2 SPP1 TNPO3 RNASEH2B TREX1 PNP HLA-DPB1 ZAP70 HLA-DPA1 TREX1 SERPING1 DCLRE1C GP1BB UFD1 ADA SLC12A3 ICOS GFI1 FOXP3 PTPN22 SPIB ICOS C2 IRF5 FCGR2B PIK3R1 ELANE WIPF1 SRP54 CTLA4 NFKB1 CAV1 STAT1 PAX4 HLA-DRB1 PTEN CASP10 TNFRSF13B ADA2 DNASE1L3 STIM1 CLCNKB DNASE1L3 GALC MS4A1 NLRP1 IFNGR1 CTLA4 RASGRP1 PTPN2 COMT RAG1 STAT4 MIF AIRE WAS RMRP HLA-DRB1 JMJD1C POU2AF1 C1GALT1C1 TNFRSF13C C1QC HIRA ADAR PTPN2 IFIH1 STAT4 PTPN22 PGM3 POLG C8A TBX1 ITCH CHD7 IRAK1 PRTN3 IL12A FOXD3 TNFRSF13B IL2RB ITPR3 TCIRG1 IL7R CR2 IL2RG STAT4 IL2RB ANKRD55 CCN2 FOXP3 IL12RB1 LMNB2 PRKCD RFXANK RNASEH2C DNASE1 C1S FASLG DDX41 MASP2 HNF1A TBX1 CAV1 CD247 MMEL1 CIITA TNFSF12 STOX1 ITK IRF5 RNASEH2A CR2 IL2RA LCK HLA-DQB1 SLC7A7 NBN SEC24C C1QB NFKB2 ADA TNFSF12 BTK PEPD FAS CCR6 LACC1 NBN C3 PRKCD TNFSF15 RFX5 PRKCD ADA2 FCGR2A CCN2 STAT1 KDM6A RAG1 KRAS SNP 0
Primary Outcomes
Description: ELISA tests for COVID-19 antibodies
Measure: COVID-19 seroconversion Time: 1 day, during routine blood collectionDescription: Case report form filled by the health professional
Measure: COVID-19 infection Time: During medical visit or phone consultation, up to 2 hoursSecondary Outcomes
Description: Descriptive analysis for each disease's rate
Measure: Seroconversion rate by disease Time: 1 day, during routine blood collectionDescription: Descriptive analysis for each country's rate
Measure: Penetration across Europe Time: 1 day, during routine blood collectionDescription: World Health Organization ordinal scale for clinical improvement at any given point of the infection, going from 0 to 8, where higher scores means worse outcome.
Measure: COVID-19 severity Time: During medical visit, up to 1 hourDescription: Descriptive analysis for overall and COVID-19-linked mortality rates
Measure: COVID-19 mortality rate Time: During contact with family members, up to 1 hourDescription: Case report form filled by the health professional
Measure: COVID-19 impact on immunomodulatory treatment Time: During medical visit, up to 1 hourDescription: Case report form filled by the patient
Measure: Patient-reported flares Time: During medical visit, up to 1 hourDescription: Fear of COVID-19 scale, going from 7 to 35, where higher scores means worse outcome.
Measure: Patient's fears towards COVID-19 Time: During medical visit, up to 1 hourDescription: Beliefs about Medicines Questionnaire, going from 11 to 55, with higher scores indicating stronger beliefs regarding medicine.
Measure: Patient's beliefs in their medicines towards COVID-19 Time: During medical visit, up to 1 hour